Subscribe To
AVRO / Avrobio Stock (AVRO): Why The Price Substantially Fell
Content Topics
Greenland
Technologies
Holding
Corporation
Gtec
Avrobio
avro
Substantially
Stock
AVRO
AVRO News
By Zacks Investment Research
October 23, 2023
Is AVROBIO (AVRO) Outperforming Other Medical Stocks This Year?
Here is how AVROBIO, Inc. (AVRO) and DaVita HealthCare (DVA) have performed compared to their sector so far this year. more_horizontal
By Zacks Investment Research
October 6, 2023
Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year?
Here is how AVROBIO, Inc. (AVRO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year. more_horizontal
By Seeking Alpha
August 12, 2023
Avrobio: Net-Net Biotech Pursuing Strategic Alternatives
After monetizing one of its pipeline candidates, Avrobio has cash well in excess of its market cap. The company announced its search for strategic alt more_horizontal
By Zacks Investment Research
July 13, 2023
AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46%
AVROBIO (AVRO) announces its decision to halt all development programs in its quest to explore strategic alternatives. The stock of the company surges more_horizontal
By InvestorPlace
May 22, 2023
Why Is AVROBIO (AVRO) Stock Up 83% Today?
AVROBIO (NASDAQ: AVRO ) stock is seeing massive gains on Monday as the company sells one of its gene therapies to Novartis (NYSE: NVS ). This deal has more_horizontal
By Benzinga
May 17, 2022
AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study
AVROBIO Inc (NASDAQ: AVRO) reported new interim data from the Phase 1/2 gene therapy trial of AVR-RD-04 for cystinosis. Cystinosis is a condition c more_horizontal
By Benzinga
February 9, 2022
After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data
Avrobio Inc's AVRO gene therapy for a rare lysosomal storage disorder showed potential durability in the first three patients more than one year af more_horizontal
By Benzinga
February 9, 2022
After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data
Avrobio Inc's AVRO gene therapy for a rare lysosomal storage disorder showed potential durability in the first three patients more than one year af more_horizontal